BRIEF-CervoMed's Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia

Reuters
27 Nov 2024
BRIEF-<a href="https://laohu8.com/S/CRVO">CervoMed</a>'s Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia

Nov 27 (Reuters) - CervoMed Inc CRVO.O:

  • CERVOMED ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO NEFLAMAPIMOD BY U.S. FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF FRONTOTEMPORAL DEMENTIA

  • CERVOMED INC - TO REPORT TOPLINE DATA FROM PHASE 2B DLB TRIAL IN DECEMBER 2024

Source text: ID:nGNX3pS5JY

Further company coverage: CRVO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10